ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis

Stock Information for ContraFect Corporation

Loading

Please wait while we load your information from QuoteMedia.